AN OPEN-LABEL STUDY IN PEDIATRIC (<18 YEARS OF AGE), SEVERE HEMOPHILIA A PARTICIPANTS (COAGULATION FACTOR ACTIVITY <1%) WITH OR WITHOUT INHIBITORS OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B PARTICIPANTS (COAGULATION FACTOR ACTIVITY ≤2%) WITH OR WITHOUT INHIBITORS COMPARING 12 MONTHS OF HISTORICAL STANDARD TREATMENT TO MARSTACIMAB PROPHYLAXIS Read more about AN OPEN-LABEL STUDY IN PEDIATRIC (
The Efficacy and Safety of Degludec Use for Glycemic Control in Critically Ill Patients: A Prospective Interventional Study Read more about The Efficacy and Safety of Degludec Use for Glycemic Control in Critically Ill Patients: A Prospective Interventional Study
Efficacy and safety of cinacalcet in children with secondary hyperparathyroidism due to Vitamin D resistant ricket, two arms, randomized clinical trial (Phase III). Read more about Efficacy and safety of cinacalcet in children with secondary hyperparathyroidism due to Vitamin D resistant ricket, two arms, randomized clinical trial (Phase III).
"Comparison of IV ketamine with Standard Analgesia for treatment of vaso occlusive crisis in sickle cell disease." Read more about "Comparison of IV ketamine with Standard Analgesia for treatment of vaso occlusive crisis in sickle cell disease."
A study comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® as well as evaluating long-term safety of somapacitan in a basket study design in children with short stature either born small for gestational age or with Turner syndrome, Noonan syndrome, or idiopathic short stature Read more about A study comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® as well as evaluating long-term safety of somapacitan in a basket study design in children with short stature either born small for gestational age or with Turner syndrome, Noonan syndrome, or idiopathic short stature
Articaine efficacy and safety for 3 years old children: A Clinical Randomized Control Trial. Read more about Articaine efficacy and safety for 3 years old children: A Clinical Randomized Control Trial.
An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment. Read more about An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment.
Non-invasive ventilation and dexmedetomidine in critically ill adults: a vanguard pragmatic randomized controlled trial (inDEX trial) Read more about Non-invasive ventilation and dexmedetomidine in critically ill adults: a vanguard pragmatic randomized controlled trial (inDEX trial)
A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non–Transfusion-Dependent Alpha or Beta Thalassemia (ENERGIZE) Read more about A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non–Transfusion-Dependent Alpha or Beta Thalassemia (ENERGIZE)
A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha or Beta Thalassemia (ENERGIZE-T) Read more about A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha or Beta Thalassemia (ENERGIZE-T)
